Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2016

February 01, 2016 Pharmaceuticals

Our licensee YooYoung Pharmaceutical launches a treatment for allergic rhinitis in South Korea, originally developed by Nippon Shinyaku

 Nippon Shinyaku announces today that our licensee YooYoung Pharmaceutical Co., Ltd. (Headquarters: Seoul, South Korea; President: Woo-Pyong Yoo) has launched, in South Korea, a dry powder spray for allergic rhinitis “Erizas® Nasal Powder 200µg 70 metered spray,” a product developed for South Korean market.

 “Erizas® Nasal Powder 200µg 70 metered spray” is a once-daily metered-dose dry powder steroid nasal spray which contains dexamethasone cipecilate as an active ingredient for 35 days.

 This product is another specification of “Erizas® Nasal Powder 200µg 28 metered spray,” which was launched in June 2012 and has been marketed by Nippon Shinyaku in Japan. Erizas® can improve three symptoms of allergic rhinitis (sneezing, nasal discharge and nasal congestion). In addition, since it is a preservative-free dry powder formulation, it causes less local irritation and less dripping off from nasal cavities.

 By launching “Erizas® Nasal Powder 200µg 70 metered spray,” which is the first dry powder steroid nasal spray in South Korea, Nippon Shinyaku hopes to expand the treatment options and contribute to the treatment of allergic rhinitis in South Korea.

 

[Reference]

Corporate name YooYoung Pharmaceutical Co., Ltd.
Established December, 1981
Headquarters 93 Yooyoung Bldg., Hyoryeong-ro, Seoul, Korea
President Mr. Woo-Pyong Yoo
Business lines Development and sale of pharmaceuticals
Employees 313 (As of January, 2016)
Sales 97.1 billion KRW (approx. 10.0 billion JPY) (2015)